Despite an initial drop in estimated glomerular filtration rate (eGFR) after 1 month of dapagliflozin, researchers say this is not associated with subsequent risk of cardiovascular or kidney events ...
Estimated GFR based on both creatinine and cystatin C better gauged risks of 8 adverse outcomes compared with using creatinine alone in older adults with nondialysis-dependent CKD. Estimated ...
Uncommon EGFR mutations, such as exon 20 insertions, account for nearly one-third of EGFR-driven NSCLC, complicating treatment strategies due to their diversity and structural challenges. Traditional ...
The estimated glomerular filtration rate (eGFR) is a blood test to assess kidney function. The formula for calculating eGFR takes the patient’s body size, age, and sex into account to predict how well ...
The U.S. Food and Drug Administration (FDA) have granted approval to Rybrevant Faspro (amivantamab and hyaluronidase-lpuj), ...
Treatment landscape of EGFR-mutant non–small cell lung cancer has evolved in the most recent years. In the metastatic setting, with combination approaches tested in first-line, whereas in the ...
Nefecon, an oral targeted-release formulation of budesonide that targets drug release into the distal ileum, provided significant improvements in the loss of kidney function in patients with ...
Black Diamond Therapeutics, Inc. is developing a next-generation EGFR inhibitor with promising early data in lung cancer. BDTX-1535 targets EGFR mutations, especially resistance drivers, with key data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback